BioSpace News Archive

Aileron Therapeutics announced that proof-of-concept data from the company’s Phase 1b study of ALRN-6924 will be featured in a late-breaking poster presentation during the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics, being held virtually October 24 – 25, 2020.

Centene and Samsung Electronics America are working together to expand access to telehealth for individuals and families living in rural and underserved communities.

The College of American Pathologists has appointed Alain C. Borczuk, MD, FCAP, chief of thoracic pathology and professor of pathology at Weill Cornell Medicine in New York, to serve as editor-in-chief of CAP’s peer-reviewed publication, Archives of Pathology and Laboratory Medicine.

Presentations highlight DecisionDx-Melanoma and DecisionDx-SCC gene expression profile tests for use in cutaneous melanoma and in cutaneous squamous cell carcinoma

Oxular Limited, a leading retinal therapeutics development company, announces it has received both Rare Paediatric Disease and Orphan Drug designations from the U.S. Food and Drug Administration for OXU-003, the Company’s proprietary drug in development for the treatment of retinoblastoma.

New data demonstrate a sustained patient benefit following SER-109 administration with a highly statistically significant 31.1% absolute reduction in the rate of C. difficile infection recurrence over 12 weeks, compared to placebo

Authored by esteemed experts in immunology and leaders at the forefront of inflammasome research at University of Miami Miller School of Medicine

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that interim data from the company’s ongoing Phase 1b/2 clinical trial (RMC-4630-02) evaluating the combination of RMC-4630 and cobimetinib (Cotellic ® ) will be reported in an oral presentation in a plenary session at the upcoming EORTC-NCI-AACR 32 nd Sy

AuraVax Therapeutics Inc. ( www.auravax.com ), a Houston, TX based biotech company developing novel vaccines to help patients defeat debilitating respiratory diseases such as SARS-CoV-2 (COVID-19), today announced it has entered in

CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today that FDA has granted Breakthrough Device Designation for the Agili-C implant™. FDA’s Brea